Tenon Medical (NASDAQ:TNON – Get Free Report) and Glaukos (NYSE:GKOS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.
Insider & Institutional Ownership
22.7% of Tenon Medical shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 17.7% of Tenon Medical shares are owned by insiders. Comparatively, 5.9% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Tenon Medical and Glaukos”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tenon Medical | $5.31 million | 0.92 | -$12.56 million | ($44.87) | -0.04 |
| Glaukos | $507.44 million | 28.98 | -$187.69 million | ($2.94) | -84.50 |
Tenon Medical has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Tenon Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tenon Medical and Glaukos’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tenon Medical | -257.85% | -907.60% | -124.84% |
| Glaukos | -24.60% | -0.97% | -0.71% |
Volatility & Risk
Tenon Medical has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for Tenon Medical and Glaukos, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tenon Medical | 1 | 0 | 1 | 0 | 2.00 |
| Glaukos | 1 | 1 | 13 | 1 | 2.88 |
Glaukos has a consensus price target of $216.71, indicating a potential downside of 12.77%. Given Glaukos’ stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than Tenon Medical.
Summary
Glaukos beats Tenon Medical on 11 of the 15 factors compared between the two stocks.
About Tenon Medical
Tenon Medical, Inc. (NASDAQ:TNON) is a medical device company focused on developing and commercializing technologies for the treatment of sacroiliac (SI) joint dysfunction. The SI joint connects the lower spine to the pelvis and can be a source of chronic lower-back and pelvic pain. The company’s primary product is the Catamaran SIJ Fusion System, a minimally invasive surgical system designed to stabilize and fuse the SI joint through a transfixation approach. The system uses a specialized implant and delivery instruments intended to support placement across the SI joint while addressing the underlying source of instability.
About Glaukos
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Receive News & Ratings for Tenon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
